Hepatitis C virus antibody detection kit and its preparation method
By incorporating magnetic bead conjugates and acrid ester conjugates into the hepatitis C virus antibody detection kit, and utilizing the combination of various stabilizers and electrolytes, the stability issues of multiple subtypes of Anti-HCV have been resolved, achieving long-term stability and extended shelf life of the kit, making it suitable for the field of biochemical detection.
Patent Information
- Application Number
- CN202410197647.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-22
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-02-22
AI Technical Summary
Existing chemiluminescent immunoassay kits for detecting hepatitis C virus antibodies suffer from poor stability and short shelf life because the working solution cannot simultaneously meet the stable preservation requirements of multiple subtypes of Anti-HCV.
By setting up working solutions for magnetic bead conjugates and acridine ester conjugates, and utilizing the synergistic interaction of various stabilizers, surfactants, and electrolytes in a buffer system, a stable working environment is provided, ensuring the stability of magnetic beads coated with hepatitis C virus antibodies and antibodies labeled with acridine esters.
The stability and shelf life of the reagent kit have been improved and extended to 18 months, which is at least 6 months longer than existing products, meeting the needs of clinical testing. In addition, the working solution components are easy to procure and low in cost.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] This invention relates to the field of biochemical detection technology, and more specifically, to a hepatitis C virus antibody detection kit and its preparation method. Background Technology
[0002] Hepatitis C is a viral hepatitis caused by infection with the hepatitis C virus (HCV). HCV is an enveloped RNA virus, composed of 9500bp–10000bp, with an open reading frame (ORF) and flanking 5' and 3' untranslated regions (NCRs), divided into structural and non-structural regions. The structural regions include a core protein region (C) and two envelope protein regions (E1 and E2), encoding the core and envelope proteins, respectively. The non-structural protein regions include NS2, NS3, NS4, and NS5, encoding functional proteins. Because HCV is a hepatotropic chronic virus, the onset and clinical symptoms of HCV infection are often atypical, frequently presenting as subclinical infection, leading to frequent missed diagnoses. Therefore, HCV detection is of great significance for the early diagnosis and clinical treatment of hepatitis C.
[0003] Currently, early screening for HCV primarily involves detecting hepatitis C virus antibodies (Anti-HCV) in serum, mainly using chemiluminescent immunoassay. Chemiluminescent immunoassay combines enzyme-linked immunosorbent assay (ELISA) with highly sensitive chemiluminescence assay and magnetic particle separation technology, improving detection sensitivity and linearity.
[0004] Current chemiluminescent immunoassay kits for detecting Anti-HCV target multiple subtypes (IgM and IgG) of the core, NS3, NS4, and NS5 proteins. The effectiveness of these kits depends on the working solution used. Because Anti-HCV is a protein, its activity is easily affected by factors such as concentration, temperature, pH, and ionic strength. Therefore, different subtypes of Anti-HCV require different working solution environments. Current working solutions cannot simultaneously ensure the stable preservation of multiple Anti-HCV subtypes, resulting in poor stability and short shelf life of the detection kits. Summary of the Invention
[0005] The purpose of this invention is to overcome the above-mentioned defects in the prior art and provide a hepatitis C virus antibody detection kit and its preparation method. By setting up a magnetic bead conjugate working solution and an acrid ester conjugate working solution in a buffer system, and combining various stabilizers, surfactants and electrolytes, a stable working environment can be provided for the magnetic beads coated with hepatitis C virus antibodies and the acrid ester-labeled hepatitis C virus antibodies, thereby improving the detection stability of the kit.
[0006] To achieve the above objectives, the technical solution of the present invention is as follows:
[0007] A hepatitis C virus antibody detection kit includes a magnetic bead conjugate working solution and an acridine ester conjugate working solution. The magnetic bead conjugate working solution comprises the following components at concentrations: a first buffer of 45mM to 55mM, a first carbohydrate stabilizer of 4% to 6%, a first surfactant of 0.1% to 0.6%, and a first protein stabilizer of 0.5% to 1.5%. The acridine ester conjugate working solution comprises the following components at concentrations: a second buffer of 45mM to 55mM, a first electrolyte of 0.8% to 1.0%, a second carbohydrate stabilizer of 2% to 4%, an amino acid stabilizer of 2% to 4%, a second protein stabilizer of 0.5% to 1.5%, and a second surfactant of 0.05% to 0.1%.
[0008] This invention also discloses a method for preparing the hepatitis C virus antibody detection kit as described above, comprising the following steps:
[0009] The magnetic beads coated with hepatitis C virus antibodies, a first buffer solution, a first carbohydrate stabilizer, a first surfactant, and a first protein stabilizer are mixed to obtain the working solution of the magnetic bead conjugate.
[0010] Acridinium ester-labeled hepatitis C virus antibody, a second buffer, a first electrolyte, a second carbohydrate stabilizer, an amino acid stabilizer, a second protein stabilizer, and a second surfactant are mixed to obtain an acridinium ester conjugate working solution.
[0011] Implementing the embodiments of the present invention will have the following beneficial effects:
[0012] The hepatitis C virus antibody detection kit provided in this invention provides a stable working environment for the magnetic beads and acrid ester-labeled hepatitis C virus antibodies coated with hepatitis C virus antibodies by combining various stabilizers, surfactants, and electrolytes in a buffer system. This improves the stability of the kit's detection. The addition of buffer ensures the stability of the working solution's pH environment. The synergistic effect of multiple stabilizers effectively enhances the stability of the hepatitis C virus antibodies. Since proteins are not easily degraded at high concentrations, adding protein stabilizers to the working solution helps preserve the hepatitis C virus antibodies. Carbohydrate stabilizers fill the gaps between protein molecules in molecular form, effectively limiting structural changes and preventing denaturation and inactivation. Amino acid stabilizers inhibit pH changes in the working solution, thus protecting the active components. Surfactants promote the dissolution of various substances in the working solution, further improving dispersibility and maintaining the spatial structure of the hepatitis C virus antibody molecules. Electrolytes control the salt concentration of the working solution. Therefore, by specifically selecting the components and amounts in the magnetic bead conjugate working solution and the acrid ester conjugate working solution, the embodiments of the present invention can maintain the stability of multiple subtypes of hepatitis C virus antibodies, maximize the preservation of the biological activity of hepatitis C virus antibodies, and extend the shelf life of hepatitis C virus antibodies.
[0013] The hepatitis C virus antibody detection kit of this invention can be stored normally for 18 months, compared to the existing hepatitis C virus antibody detection kits (chemiluminescent immunoassay) from manufacturers such as Abbott, Roche, Antu, and Mindray, which have a shelf life of only 12 months. This significantly improves the stability and shelf life of the kit, better meeting the needs of clinical testing. Furthermore, the components used in the working solution are readily available and inexpensive. Detailed Implementation
[0014] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0015] A hepatitis C virus antibody detection kit includes a magnetic bead conjugate working solution and an acridine ester conjugate working solution. The magnetic bead conjugate working solution comprises the following components at concentrations: a first buffer of 45 mM to 55 mM, a first carbohydrate stabilizer of 4% to 6%, a first surfactant of 0.1% to 0.6%, and a first protein stabilizer of 0.5% to 1.5%. The acridine ester conjugate working solution comprises the following components at concentrations: a second buffer of 45 mM to 55 mM, a first electrolyte of 0.8% to 1.0%, a second carbohydrate stabilizer of 2% to 4%, an amino acid stabilizer of 2% to 4%, a second protein stabilizer of 0.5% to 1.5%, and a second surfactant of 0.05% to 0.1%.
[0016] Specifically, the hepatitis C virus antibody detection kit of the present invention, by setting up a magnetic bead conjugate working solution and an acridil ester conjugate working solution in a buffer system, combines various stabilizers, surfactants, and electrolytes to ensure the stability and shelf life of the acridil ester-labeled hepatitis C virus antibody and the magnetic beads coated with the hepatitis C virus antibody. This solves the problems of unstable binding and easy hydrolysis of acridil ester and magnetic beads with antibodies, thereby improving the stability and shelf life of the kit. At the same time, the working solution formulation provided by the present invention is relatively simple, improving the feasibility and controllability of the production process.
[0017] In one specific embodiment, the first buffer and the second buffer each include one or more of MES buffer, Tris buffer, HEPES buffer, TES buffer, PBS buffer, and MOPS buffer. Specifically, adding buffers ensures the stability of the pH environment of the working solution.
[0018] In one specific embodiment, the first carbohydrate stabilizer and the second carbohydrate stabilizer each include one or more of trehalose, lactose, sucrose, mannitol, pentaerythritol, and glucose. Specifically, the carbohydrate stabilizers fill the gaps between protein molecules in molecular form, effectively limiting changes in the internal structure of the protein molecules, thereby preventing protein denaturation and inactivation.
[0019] In one specific embodiment, the first protein stabilizer and the second protein stabilizer each comprise one or two of bovine serum albumin (BSA), tryptone, and basic casein. Specifically, since proteins are not easily degraded at high concentrations, adding protein stabilizers to the working solution is beneficial for the preservation of hepatitis C virus antibodies.
[0020] Preferably, the first and second protein stabilizers are BSA. By adding BSA as a stabilizer, the antibodies on the magnetic beads and acridine ester can be protected. BSA can mimic various large proteins or enzymes in serum. These biomolecules can rapidly form a protein crown on the surface of the magnetic beads. The formed protein crown can reduce the mutual attraction and contact between the immunomagnetic beads, reduce non-specific binding, and maintain the stability of the magnetic beads coated with hepatitis C virus antibodies and the hepatitis C virus antibodies labeled with acridine ester.
[0021] In one specific embodiment, the first surfactant and the second surfactant each comprise one or more of the following: sodium dodecylbenzenesulfonate, fatty alcohol polyoxyethylene ether sulfate, sodium oleoyloxyethanesulfonate, Tween 20, Tween 80, Triton 100, and Triton 405. Specifically, the addition of surfactants promotes the dissolution of various substances in the working solution, further improves dispersibility, and maintains the spatial structure of the hepatitis C virus antibody molecules unchanged.
[0022] In one specific embodiment, the amino acid stabilizer includes one or more of glycine, tyrosine, tryptophan, lysine, arginine, and proline. Specifically, the amino acid stabilizer can inhibit pH changes in the working solution, thereby protecting the active components.
[0023] In one specific embodiment, the first electrolyte includes one or more of sodium chloride, potassium chloride, sodium carbonate, potassium carbonate, magnesium chloride, and aluminum chloride. Specifically, the addition of electrolytes controls the salt concentration of the working solution, reducing potential non-specific antigen-antibody binding.
[0024] In one specific embodiment, the hepatitis C virus antibody detection kit further includes a sample processing solution; the sample processing solution comprises the following components at the following concentrations: a 45mM–55mM third buffer, 0.8%–1.0% second electrolyte, 0.5%–1.0% third protein stabilizer, 0.02%–0.03% iodoacetamide, and 0.5%–3% third surfactant. Specifically, by combining the third protein stabilizer, iodoacetamide, third surfactant, and electrolyte in a buffer system, the dissolution of each component in the sample pretreatment solution can be promoted, preventing the formation of disulfide bonds and subsequent inactivation of proteins. This ensures a stable reaction environment and prevents fluctuations and influences on the detection results, thereby improving the stability of the sample processing solution and guaranteeing the accuracy of the detection results.
[0025] In one specific embodiment, the third buffer includes one or more of MES buffer, Tris buffer, HEPES buffer, TES buffer, PBS buffer, and MOPS buffer.
[0026] In one specific embodiment, the third protein stabilizer includes one or two of bovine serum albumin, tryptone, and basic casein.
[0027] In one specific embodiment, the third surfactant includes one or more of sodium dodecylbenzenesulfonate, fatty alcohol polyoxyethylene ether sulfate, sodium oleoyloxyethanesulfonate, Tween 20, Tween 80, Triton 100, and Triton 405.
[0028] In one specific embodiment, the second electrolyte includes one or more of sodium chloride, potassium chloride, sodium carbonate, potassium carbonate, magnesium chloride, and aluminum chloride.
[0029] In one specific embodiment, the sample processing solution further includes a first preservative at a concentration of 0.2% to 0.3%; the magnetic bead conjugate working solution further includes a second preservative at a concentration of 0.1% to 0.15%; and the acridine ester conjugate working solution further includes a third preservative at a concentration of 0.1% to 0.15%.
[0030] In one specific embodiment, the first preservative, the second preservative, and the third preservative each include one or more of BND, Proclin 200, Proclin 300, and Proclin 500. Specifically, the preservatives can inhibit the growth of microorganisms, allowing the reagent to be stored for a long time without deterioration.
[0031] Furthermore, the present invention also discloses a method for preparing a hepatitis C virus antibody detection kit as described in any embodiment of the present invention, comprising the following steps:
[0032] 1) Mix magnetic beads coated with hepatitis C virus antibodies, a first buffer solution, a first carbohydrate stabilizer, a first surfactant, and a first protein stabilizer to obtain a working solution of magnetic bead conjugate.
[0033] 2) Mix the acridinium ester-labeled hepatitis C virus antibody, the second buffer, the first electrolyte, the second carbohydrate stabilizer, the amino acid stabilizer, the second protein stabilizer, and the second surfactant to obtain the acridinium ester conjugate working solution.
[0034] In one specific embodiment, the preparation method further includes the following steps:
[0035] The third buffer, the second electrolyte, the third protein stabilizer, iodoacetamide, and the third surfactant are mixed to obtain the sample processing solution.
[0036] Furthermore, the detection method of the hepatitis C virus antibody detection kit of the present invention includes the following steps: after treating the sample to be tested with a sample processing solution, magnetic bead working solution and acridine ester conjugate working solution are added. The magnetic beads coated with hepatitis C virus antibodies and the hepatitis C virus antibodies labeled with acridine ester bind to the hepatitis C virus antigen respectively to form a "sandwich" structure, thereby realizing the detection and quantification of hepatitis C virus.
[0037] The following are specific embodiments.
[0038] Example 1
[0039] The hepatitis C virus antibody detection kit of this embodiment includes a magnetic bead conjugate working solution, an acrid ester conjugate working solution, and a sample processing solution.
[0040] The working solution for the magnetic bead conjugate comprises the following components at the following concentrations: 50 mM Tris buffer, 5% sucrose, 0.1% Tween 20, 1.5% BSA, and 0.1% Proclin 300.
[0041] The acridine ester conjugate working solution comprises the following components at the following concentrations: 50 mM MES buffer, 0.9% NaCl, 3% sucrose, 3% glycine, 1% BSA, 0.05% Tween 20, 0.1% BND, and 0.1% Proclin 300.
[0042] The sample processing solution contains the following components at the following concentrations: 50 mM MES buffer, 0.9% NaCl, 0.5% BSA, 1% alkaline casein, 0.02% iodoacetamide, 1.0% Triton 405, 0.05% Tween 20, 0.1% BND, and 0.1% Proclin 300.
[0043] The preparation method of the hepatitis C virus antibody detection kit in this embodiment includes the following steps:
[0044] Weigh according to the above proportions.
[0045] 1) Mix magnetic beads coated with hepatitis C virus antibody, Tris buffer, sucrose, sodium dodecylbenzenesulfonate, Tween 20, tryptone, BSA and Proclin 300 to obtain the working solution of magnetic bead conjugate.
[0046] 2) Mix acridinium ester-labeled hepatitis C virus antibody, MES buffer, NaCl, sucrose, glycine, BSA, Tween 20, BND and Proclin 300 to obtain the working solution of acridinium ester conjugate.
[0047] 3) Mix MES buffer, NaCl, BSA, alkaline casein, iodoacetamide, Triton 405, Tween 20, BND and Proclin 300 to obtain the sample processing solution.
[0048] Example 2
[0049] The hepatitis C virus antibody detection kit of this embodiment includes a magnetic bead conjugate working solution, an acrid ester conjugate working solution, and a sample processing solution.
[0050] The magnetic bead conjugate working solution comprises the following components at the following concentrations: 55 mM HEPES buffer, 6% trehalose, 0.02% sodium dodecylbenzenesulfonate, 0.1% Tween 20, 0.5% tryptone, 1% BSA, and 0.1% Proclin 300.
[0051] The acridine ester conjugate working solution comprises the following components at the following concentrations: 55 mM MES buffer, 0.8% potassium chloride, 2% mannitol, 2% arginine, 0.5% BSA, 0.05% Triton 100, 0.05% BND, and 0.05% Proclin 300.
[0052] The sample processing solution contains the following components at the following concentrations: 50 mM MES buffer, 0.9% NaCl, 0.5% BSA, 1% alkaline casein, 0.02% iodoacetamide, 1.0% Triton 405, 0.05% Tween 20, 0.1% BND, and 0.1% Proclin 300.
[0053] The preparation method in this embodiment is the same as that in Example 1.
[0054] Example 3
[0055] The hepatitis C virus antibody detection kit of this embodiment includes a magnetic bead conjugate working solution, an acrid ester conjugate working solution, and a sample processing solution.
[0056] The magnetic bead conjugate working solution comprises the following components at the following concentrations: 45 mM PBS buffer, 6% glucose, 0.5% sodium dodecylbenzenesulfonate, 0.1% tryptone, and 0.2% Proclin 300.
[0057] The acridine ester conjugate working solution comprises the following components at the following concentrations: 45 mM PBS buffer, 0.8% magnesium chloride, 2% glucose, 2% tyrosine, 0.5% BSA, 0.05% sodium dodecylbenzenesulfonate, and 0.15% Proclin 300.
[0058] The sample processing solution contains the following components at the following concentrations: 50 mM MES buffer, 0.9% NaCl, 0.5% BSA, 1% alkaline casein, 0.02% iodoacetamide, 1.0% Triton 405, 0.05% Tween 20, 0.1% BND, and 0.1% Proclin 300.
[0059] The preparation method in this embodiment is the same as that in Example 1.
[0060] Test case
[0061] The magnetic bead conjugate working solution, sample processing solution, and acridil ester conjugate working solution from Example 1 were aliquoted into three portions. One portion was stored at 2℃~8℃ and designated as Group A; one portion was accelerated at 37℃ for 7 days and designated as Group B; and one portion was accelerated at 37℃ for 10 days and designated as Group C. Negative samples, gray area samples, and positive samples were tested respectively, and the signal value deviation was compared. If the signal value deviation was within 10%, it indicated good stability. The results are shown in Table 1. Table 1 shows the stability test data of Example 1.
[0062] Table 1. Stability test data for Example 1
[0063]
[0064] According to the results in Table 1, the signal deviation of the accelerated stability of Example 1 on days 7 and 10 is within 10%, which reflects that the magnetic beads coated with hepatitis C virus antibody and the hepatitis C virus antibody labeled with acridinium ester can be stable for a long time in the working solution.
[0065] In the test examples of this invention, Experiment 2-3 all have the same effect as Experiment 1.
[0066] Therefore, by specifically selecting the components and amounts in the magnetic bead conjugate working solution and the acridine ester conjugate working solution, this invention can maintain the stability of hepatitis C virus antibodies, maximize the preservation of their biological activity, and extend their shelf life. The hepatitis C virus antibody detection kit of this invention can be stored normally for 18 months, compared to the existing hepatitis C virus antibody detection kits from manufacturers such as Abbott, Roche, Antu, and Mindray, which only have a shelf life of 12 months.
[0067] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.
Claims
1. An antibody test kit for hepatitis C virus, characterized by comprising: It includes a sample processing solution, a magnetic bead conjugate working solution, and an acrid ester conjugate working solution, wherein the sample processing solution is used to process the sample to be tested; The sample processing solution comprises the following components at the following concentrations: 45mM~55mM third buffer, 0.8%~1.0% second electrolyte, 0.5%~1.0% third protein stabilizer, 0.02%~0.03% iodoacetamide, 0.5%~3% third surfactant, and 0.2%~0.3% first preservative; The working solution of the magnetic bead conjugate comprises components of the following concentrations: The first buffer solution is 45mM~55mM, the first carbohydrate stabilizer is 4%~6%, the first surfactant is 0.1%~0.6%, the first protein stabilizer is 0.5%~1.5%, and the second preservative is 0.1%~0.15%. The acridine ester conjugate working solution comprises the following components at the following concentrations: The solution contains a second buffer of 45mM to 55mM, a first electrolyte of 0.8% to 1.0%, a second carbohydrate stabilizer of 2% to 4%, an amino acid stabilizer of 2% to 4%, a second protein stabilizer of 0.5% to 1.5%, a second surfactant of 0.05% to 0.1%, and a third preservative of 0.1% to 0.15%. The first sugar stabilizer and the second sugar stabilizer each include one or more of trehalose, sucrose, mannitol and glucose; The amino acid stabilizer includes one or more of glycine, tyrosine, tryptophan, arginine, and proline. The first protein stabilizer and the second protein stabilizer are bovine serum albumin; The first preservative, the second preservative, and the third preservative each include one or more of BND, Proclin 200, Proclin 300, and Proclin 500.
2. The hepatitis C virus antibody detection kit according to claim 1, characterized in that, The first buffer and the second buffer each include one or more of MES buffer, Tris buffer, HEPES buffer, TES buffer, PBS buffer and MOPS buffer.
3. The hepatitis C virus antibody detection kit according to claim 1, characterized in that, The first surfactant and the second surfactant each comprise one or more of sodium dodecylbenzenesulfonate, fatty alcohol polyoxyethylene ether sulfate, sodium oleoyloxyethanesulfonate, Tween 20, Tween 80, Triton 100, and Triton 405.
4. The hepatitis C virus antibody detection kit according to claim 1, characterized in that, The first electrolyte includes one or more of sodium chloride, potassium chloride, sodium carbonate, potassium carbonate, magnesium chloride, and aluminum chloride.
5. The hepatitis C virus antibody detection kit according to claim 1, characterized in that, The third buffer includes one or more of the following: MES buffer, Tris buffer, HEPES buffer, TES buffer, PBS buffer, and MOPS buffer. The third protein stabilizer includes one or two of bovine serum albumin, tryptone, and basic casein; The third surfactant includes one or more of sodium dodecylbenzenesulfonate, fatty alcohol polyoxyethylene ether sulfate, sodium oleoyloxyethanesulfonate, Tween 20, Tween 80, Triton 100 and Triton 405. The second electrolyte includes one or more of sodium chloride, potassium chloride, sodium carbonate, potassium carbonate, magnesium chloride, and aluminum chloride.
6. A method for preparing a hepatitis C virus antibody detection kit as described in any one of claims 1 to 5, characterized in that, Includes the following steps: The third buffer, the second electrolyte, the third protein stabilizer, iodoacetamide, and the third surfactant are mixed to obtain the sample processing solution; The magnetic beads coated with hepatitis C virus antibodies, a first buffer solution, a first carbohydrate stabilizer, a first surfactant, and a first protein stabilizer are mixed to obtain the working solution of the magnetic bead conjugate. Acridinium ester-labeled hepatitis C virus antibody, a second buffer, a first electrolyte, a second carbohydrate stabilizer, an amino acid stabilizer, a second protein stabilizer, and a second surfactant are mixed to obtain an acridinium ester conjugate working solution.
Citation Information
Patent Citations
Diluent enabling stability for acridinium ester antigen-antibody conjugate and preparation method of diluent
CN105628914A
Acridinium ester chemiluminescence-based streptavidin magnetic bead-biotin amplification reaction system and detection kit
CN110146692A
